A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
Eisai Inc.
Eisai Inc.
Merck Sharp & Dohme LLC
Takeda
Rigshospitalet, Denmark
Brown University
Barbara Ann Karmanos Cancer Institute
SWOG Cancer Research Network
Checkpoint Therapeutics, Inc.
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
Calithera Biosciences, Inc
Genprex, Inc.
Peking University First Hospital
National Institutes of Health Clinical Center (CC)
Eli Lilly and Company
University of Arizona
Amgen
Stanford University
Boehringer Ingelheim
University of Kentucky
National Cancer Institute (NCI)